Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02307682 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,775
- Enrollment target
NCT02307682: Completed Phase 3 study, sponsored by Alcon Research.
NCT02307682 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 1,775 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (130% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02307682, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,775 participants
- Enrollment target
Study Summary
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
Primary Outcome
BCVA (with spectacles or other visual corrective devices) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Interventions
- DRUG Brolucizumab ophthalmic solution
- DRUG Aflibercept ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,775 participants |
| Start Date | 2014-12-08 |
| Est. Completion | 2018-03-28 |
| Phase | Phase 3 |
What the finished NCT02307682 record still lists
NCT02307682 is an interventional study that assigns participants to a tested intervention. Its 1,775 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (130% higher).
The record links to 0 conditions, and to 2 interventions - of which Brolucizumab ophthalmic solution is the first listed.
NCT02307682 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02307682 about?
NCT02307682 is a clinical study titled "Efficacy and Safety of RTH258 Versus Aflibercept - Study 1". The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-re...
What is the current status of trial NCT02307682?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,775 participants. The study started on 2014-12-08. Estimated completion is 2018-03-28.
What interventions are being tested in trial NCT02307682?
The interventions under investigation include: Brolucizumab ophthalmic solution (DRUG), Aflibercept ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT02307682?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02307682's enrollment target sits among peer trials
1,775 126th of 2000 higher than 1,875 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03067181 · 1,780 participants · Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- NCT06526650 · 1,780 participants · NA
'Ai Pono Cooking Demonstrations
- NCT05770570 · 1,785 participants · Phase 2
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
- NCT06239688 · 1,764 participants · NA
Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI